Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research context
Abstract Onset‐predictive biomarker tests (OPBTs) for genetic frontotemporal dementia (FTD) may predict symptom onset in coming years. OPBT results could be used as inclusion criterion for clinical trials for FTD, but this requires disclosure of OPBT results to potential participants for informed co...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/dad2.70133 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849423803993554944 |
|---|---|
| author | Charlotte H. Graafland Laura Donker Kaat Edo Richard John C. vanSwieten Harro Seelaar Eline M. Bunnik |
| author_facet | Charlotte H. Graafland Laura Donker Kaat Edo Richard John C. vanSwieten Harro Seelaar Eline M. Bunnik |
| author_sort | Charlotte H. Graafland |
| collection | DOAJ |
| description | Abstract Onset‐predictive biomarker tests (OPBTs) for genetic frontotemporal dementia (FTD) may predict symptom onset in coming years. OPBT results could be used as inclusion criterion for clinical trials for FTD, but this requires disclosure of OPBT results to potential participants for informed consent. This creates a dilemma, as disclosure may be psychologically burdensome. Yet, individuals at risk of FTD may value OPBTs to relieve uncertainty and support planning for the future. This article provides an overview of considerations regarding disclosure using four themes (actionability, respect for autonomy and informed consent, psychological impact, social and societal impact), based on literature on return of individual research results and biomarker disclosure in Alzheimer's disease. Based on this, we argue that clinical validity and context of use are important considerations, and suggest that (1) counseling facilitates informed decision making, (2) clinical and psychological follow‐up provides necessary support, and (3) impacts may be monitored in a pilot study. Highlights Ethical considerations regarding disclosure of onset‐predictive biomarker test (OPBT) results include actionability, respect for autonomy and informed consent, psychological impact, and social and societal impact. The weight of each consideration depends heavily on the clinical validity of the OPBT results and the context of use. OPBT result disclosure to individuals at risk of genetic frontotemporal dementia (FTD) for clinical trial recruitment seems ethically acceptable. We suggest embedding OPBT results disclosure in counseling, follow‐up, and a pilot study on impacts of OPBT results disclosure. |
| format | Article |
| id | doaj-art-0e2c9de89bcb43b1901756120abd36e4 |
| institution | Kabale University |
| issn | 2352-8729 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
| spelling | doaj-art-0e2c9de89bcb43b1901756120abd36e42025-08-20T03:30:28ZengWileyAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring2352-87292025-04-01172n/an/a10.1002/dad2.70133Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research contextCharlotte H. Graafland0Laura Donker Kaat1Edo Richard2John C. vanSwieten3Harro Seelaar4Eline M. Bunnik5Department of Public HealthProgram Medical Ethics, Philosophy and History of MedicineErasmus University Medical CenterRotterdam the NetherlandsDepartment of Clinical GeneticsErasmus University Medical CenterRotterdamthe NetherlandsDepartment of NeurologyDonders Institute for BrainCognition and Behaviour, Radboud University Medical CenterNijmegenthe NetherlandsDepartment of Neurology and Alzheimer CenterErasmus University Medical CenterRotterdamthe NetherlandsDepartment of Neurology and Alzheimer CenterErasmus University Medical CenterRotterdamthe NetherlandsDepartment of Public HealthProgram Medical Ethics, Philosophy and History of MedicineErasmus University Medical CenterRotterdam the NetherlandsAbstract Onset‐predictive biomarker tests (OPBTs) for genetic frontotemporal dementia (FTD) may predict symptom onset in coming years. OPBT results could be used as inclusion criterion for clinical trials for FTD, but this requires disclosure of OPBT results to potential participants for informed consent. This creates a dilemma, as disclosure may be psychologically burdensome. Yet, individuals at risk of FTD may value OPBTs to relieve uncertainty and support planning for the future. This article provides an overview of considerations regarding disclosure using four themes (actionability, respect for autonomy and informed consent, psychological impact, social and societal impact), based on literature on return of individual research results and biomarker disclosure in Alzheimer's disease. Based on this, we argue that clinical validity and context of use are important considerations, and suggest that (1) counseling facilitates informed decision making, (2) clinical and psychological follow‐up provides necessary support, and (3) impacts may be monitored in a pilot study. Highlights Ethical considerations regarding disclosure of onset‐predictive biomarker test (OPBT) results include actionability, respect for autonomy and informed consent, psychological impact, and social and societal impact. The weight of each consideration depends heavily on the clinical validity of the OPBT results and the context of use. OPBT result disclosure to individuals at risk of genetic frontotemporal dementia (FTD) for clinical trial recruitment seems ethically acceptable. We suggest embedding OPBT results disclosure in counseling, follow‐up, and a pilot study on impacts of OPBT results disclosure.https://doi.org/10.1002/dad2.70133biomarkerclinical trialdisclosureethicsfrontotemporal dementiainformed consent |
| spellingShingle | Charlotte H. Graafland Laura Donker Kaat Edo Richard John C. vanSwieten Harro Seelaar Eline M. Bunnik Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research context Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring biomarker clinical trial disclosure ethics frontotemporal dementia informed consent |
| title | Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research context |
| title_full | Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research context |
| title_fullStr | Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research context |
| title_full_unstemmed | Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research context |
| title_short | Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research context |
| title_sort | ethics of disclosure of onset predictive biomarker test results for genetic frontotemporal dementia in the research context |
| topic | biomarker clinical trial disclosure ethics frontotemporal dementia informed consent |
| url | https://doi.org/10.1002/dad2.70133 |
| work_keys_str_mv | AT charlottehgraafland ethicsofdisclosureofonsetpredictivebiomarkertestresultsforgeneticfrontotemporaldementiaintheresearchcontext AT lauradonkerkaat ethicsofdisclosureofonsetpredictivebiomarkertestresultsforgeneticfrontotemporaldementiaintheresearchcontext AT edorichard ethicsofdisclosureofonsetpredictivebiomarkertestresultsforgeneticfrontotemporaldementiaintheresearchcontext AT johncvanswieten ethicsofdisclosureofonsetpredictivebiomarkertestresultsforgeneticfrontotemporaldementiaintheresearchcontext AT harroseelaar ethicsofdisclosureofonsetpredictivebiomarkertestresultsforgeneticfrontotemporaldementiaintheresearchcontext AT elinembunnik ethicsofdisclosureofonsetpredictivebiomarkertestresultsforgeneticfrontotemporaldementiaintheresearchcontext |